MetaVia Inc. (NASDAQ:MTVA – Free Report) – Stock analysts at HC Wainwright issued their Q4 2024 earnings estimates for MetaVia in a research report issued on Monday, December 30th. HC Wainwright analyst E. Arce forecasts that the company will post earnings of ($0.74) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.91) per share. HC Wainwright also issued estimates for MetaVia’s FY2025 earnings at ($2.61) EPS and FY2026 earnings at ($2.73) EPS.
MetaVia Stock Up 2.5 %
NASDAQ MTVA opened at $2.03 on Wednesday. MetaVia has a fifty-two week low of $1.51 and a fifty-two week high of $6.75.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Further Reading
- Five stocks we like better than MetaVia
- What is the Australian Securities Exchange (ASX)
- Work and Play: Investing in the Rise of Bleisure Travel
- Where Do I Find 52-Week Highs and Lows?
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
